Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) are at a new all time high at $38.15 in pre-market trading Thursday after the company had its price target raised to $54 from $28 at Stifel. Tetraphase yesterday announced positive top-line results from the Phase 3 IGNITE 1 trial, the company’s Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infections, the first of two pivotal trials that Stifel believes could lead to an NDA submission in 4Q15 and approval in 2016.
On valuation measures, Tetraphase Pharmaceuticals shares have a price/sales of 116.14. EPS is ($2.28). Currently there are 9 analysts that rate TTPH a ‘Buy’. No analyst rates it a ‘Sell’. TTPH has a median Wall Street price target of $28.00 with a high target of $33.00.
In the past 52 weeks, shares of Watertown, Massachusetts-based firm have traded between a low of $8.01 and a high of $33.22. Shares are up 174.07% year-over-year and 145.49% year-to-date.
OvaScience, Inc. (OVAS) was raised to $100 from $40, versus a prior $34.96 close, at H.C. Wainwright on Thursday.
OvaScience shares recently rose 19.37% to $41.60, a new all time high. The stock is up more than 282% this year.
Mobile Telesystems OJSC (MBT) are up almost 25% to $8.00 in pre-market trading Thursday. Not seeing any news or rumors to account for the move.
Mobile Telesystems is a Moscow-based provide of mobile and fixed line voice and data telecommunications services in Russia. Its stock has a 52-week trading range of $5.85 to $21.87. The T-12 operating margin at MBT is 25.66%. The name‘s revenue for the same period is $13.16 billion. Mobile Telesystems price/sales is 0.49.
Shares in the $6.39 billion market cap company are down 67.88% year-over-year, and 70.27% year-to-date.
Silicon Image, Inc. (SIMG) plunged more than 23 percent in pre-market hours trade after the provider of multimedia connectivity solutions issued downside guidance for FY15 (Dec), saying it expects revs to decline 10% YoY, “due to a reduction in mobile design wins at one of its largest customers”.
“Although we believe that both our CE and licensing businesses will remain strong, we now anticipate top line 2015 revenues to be down compared to 2014,” said Camillo Martino, CEO of Silicon Image.
Silicon Image, Inc., currently valued at $523.39M, has a median Wall Street price target of $7.75 with a high target of $10.00. In the past 52 weeks, shares of Sunnyvale, California-based company have traded between a low of $4.10 and a high of $7.33 with the 50-day MA and 200-day MA located at $5.81 and $5.17 levels, respectively. Additionally, shares of SIMG trade at a P/E ratio of 1.27 and have a Relative Strength Index (RSI) and MACD indicator of 66.10 and +0.23, respectively.
SIMG currently prints a one year loss of about 4.50% and a year-to-date loss of around 15%.
Rite Aid Corporation (RAD) is seeing notable move off the open following better than expected 3Q earnings and improved guidance.
Rite Aid Corporation shares are currently priced at 22.36x this year’s forecasted earnings compared to the industry’s 12.09x earnings multiple. Ticker has a PEG and forward P/E ratio of 0.49 and 15.54, respectively. Price/Sales for the same period is 0.23 while EPS is $0.27. Currently there are 7 analysts that rate RAD a ‘Buy’, 3 rate it a ‘Hold’. No analyst rates it a ‘Sell’. RAD has a median Wall Street price target of $6.63 with a high target of $8.00.
In the past 52 weeks, shares of Camp Hill, Pennsylvania-based drugstore retailer have traded between a low of $4.42 and a high of $8.62 and are now up nearly 16% at $7.04. Shares are up 6.69% year-over-year and 19.76% year-to-date.